• Like

Continuous Glucose Monitoring in Europe: Revolutionizing Diabetes Care

  • 2,909 views
Uploaded on

As per the International Diabetes Federation, in 2010, the adult population with diabetes is likely to reach 55.2 million in Europe and around 285 million people worldwide will live with diabetes in …

As per the International Diabetes Federation, in 2010, the adult population with diabetes is likely to reach 55.2 million in Europe and around 285 million people worldwide will live with diabetes in the same year. This presentation presents the market opportunities for continuous glucose monitoring as the most convenient and reliable for patients and discusses the different technologies available.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
No Downloads

Views

Total Views
2,909
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
57
Comments
0
Likes
3

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Continuous Glucose Monitoring in Europe: Revolutionizing Diabetes Care Akanksha Joshi, Senior Research Analyst Healthcare April 22, 2010
  • 2. Agenda • Diabetes – A growing concern • Glucose monitoring • Continuous Glucose Monitoring • Market Trends – Growth factors, Restraints • Market Potential • Key Focus Points 2
  • 3. Diabetes – A Growing Concern As per the International Diabetes Federation, in 2010, the adult population with diabetes is likely to reach 55.2 million in Europe and around 285 Also the national prevalence rate million people worldwide will live with diabetes of diabetes varies from country to in the same year. country in Europe – 2.1 per cent in Iceland to 12.0 per cent in Germany. Further it is estimated that 630,000 people would succumb to death due to diabetes in 2010. This number accounts The IDF further indicates that in 2010 for 11 per cent of deaths in the age group the healthcare expenditure on diabetes of 20-79. is likely to be US$ 106 billion in the European region a share of 28 per cent of the global expenditure. Source: IDF Diabetes Atlas fourth edition 3
  • 4. Prevalence percent of Diabetes Germany is the biggest market owing 9.0 to the largest diabetic population in Europe. The diabetic population is expected to be 7.5 million in 2010. 8.0 7.0 P er c ent of population 6.0 5.0 4.0 3.0 2.0 1.0 0.0 Belgium Denmark Finland France Germany Italy LuxembourgNetherlands Norway Spain Sweden United Kingdom Country 2009 2012 Source: Frost & Sullivan 4
  • 5. Glucose Monitoring An Overview An Overview •The traditional method of monitoring glucose involves sticking fingerstick to gain access to •The traditional method of monitoring glucose involves sticking fingerstick to gain access to glucose. The inconvenience associated with this method makes ititdifficult for the patient to glucose. The inconvenience associated with this method makes difficult for the patient to maintain tight glycemic level because of the inconvenience involved. maintain tight glycemic level because of the inconvenience involved. •Episodic monitoring of glucose does not provide information about changes in level of Episodic monitoring of glucose does not provide information about changes in level of • glucose between two consecutive measurements. Unawareness regarding aa patient falling glucose between two consecutive measurements. Unawareness regarding patient falling or rising glycemic level could lead to serious medical condition. or rising glycemic level could lead to serious medical condition. •Continuous Glucose monitoring is of help for patients who have vast fluctuations in their •Continuous Glucose monitoring is of help for patients who have vast fluctuations in their glycemic level. Using this method the treatment plan of aadiabetic can be well adjusted all glycemic level. Using this method the treatment plan of diabetic can be well adjusted all through the day. The method also relieves the patient of sticking finger stick and getting rid through the day. The method also relieves the patient of sticking finger stick and getting rid of the discomfort caused. of the discomfort caused. 5
  • 6. Continuous Glucose Monitoring A step ahead .... A step ahead •A continuous glucose monitor uses a sensor and transmitter attached to the body that •A continuous glucose monitor uses a sensor and transmitter attached to the body that communicate with aahandheld receiver or an insulin pump. communicate with handheld receiver or an insulin pump. •The calibration of CGM is based on the standard meter. The average number of calibrations •The calibration of CGM is based on the standard meter. The average number of calibrations would be two fingertip blood glucose test per 24 hours. Calibrating the CGM on aa regular would be two fingertip blood glucose test per 24 hours. Calibrating the CGM on regular basis is aamust for accurate readings. basis is must for accurate readings. •CGM measure glucose in the interstitial fluid so the lag effect seems to be evident when •CGM measure glucose in the interstitial fluid so the lag effect seems to be evident when compared to traditional blood glucose level. CGM is advantageous and accurate as the compared to traditional blood glucose level. CGM is advantageous and accurate as the glucose level rises in the blood first and then increases in the interstitial fluid. glucose level rises in the blood first and then increases in the interstitial fluid. 6
  • 7. Continuous Glucose Monitoring – different technologies involved This technology involves a small incision in to the body to acquire blood or Interstitial Fluid (ISF) Minimally through micro channels on the skin surface. The replacement Invasive period of these sensors varies from 3 days to 5 days to a maximum of 7 days. The patient Implantable comfort level is quite low in Based on the treatment for this method. Technology The sensor is placed in the body for minimum period of 6 months to a year. This technology Non – Invasive involves a threat from infections during the placement and This technology incorporates optical replacement of sensors. Major methods and the sensor placement issue concerning the research depends on the usage. The accuracy and development team in involved in this approach is debatable regards to this technique is the and depends on the size and the optical biocompatibility of the sensor. method used. Source: Frost & Sullivan 7
  • 8. In the competition Company Products Medtronic Inc. MiniMed Paradigm® Veo™ System Guardian REAL-Time Continuous Glucose Monitoring System Abbott Laboratories Abbott FreeStyle Navigator® DexCom Inc SEVEN® PLUS A. Menarini GlucoDay®S Source: Frost & Sullivan 8
  • 9. Growth Factors: Revolutionising the Market space Increase in requirement of glucose monitoring devices Ease of use and better patient comfort likely to spur market growth Awareness regarding diabetes among the people as well as government organisation Integration of insulin pump with the monitoring devices Source: Frost & Sullivan 9
  • 10. Roadblocks for the revolution in the CGM Industry Reimbursement of the device Reliance on Physician for adopting the technology Lack of awareness and fear of new technology Clinically benchmarked and affordable technologies available in the market Source: Frost & Sullivan 10
  • 11. Market Potential – Glucose Monitoring The continuous glucose monitoring market in Europe has seen increased penetration in recent times. Competitive Per cent growth analysis suggests that with the entry of new market participants, the dynamics of the market would change in Market 2010. Potential Total CGM Total SBGM .... Revenue 2009 • Market Potential For Blood Glucose Monitoring .... If the concerns regarding reimbursement are resolved the CGM market would be seen replacing the self blood glucose • Traditional Blood monitoring market. Glucose Monitors Market • CGM Market Source : Frost & Sullivan 11
  • 12. Key Focus Points Strategic Alliances Strategic Alliances Clinicians Support Cost Benefit Evidence Source: Frost & Sullivan 12
  • 13. Next Steps Request a strategic approach document for a Growth Partnership Service or Growth Consulting Service to support you and your team to accelerate the growth of your company. (myfrost@frost.com) +44 (0)20 7343 8383 Join us at our annual Growth, Innovation and Leadership 2010: A Frost & Sullivan Global Congress on Corporate Growth London, United Kingdom (www.gil-global.com) Register for the next Chairman’s Series on Growth: M&A - Identifying Stealth Opportunities Beneath Your Radar & Other Best Practices 12 May 2010 10:00 AM BST (www.frost.com/growthEU) Register for Frost & Sullivan’s Growth Opportunity Newsletter and keep abreast of innovative growth opportunities (www.frost.com/news) 13
  • 14. Your Feedback is Important to Us What would you like to see from Frost & Sullivan? Growth Forecasts? Competitive Structure? Emerging Trends? Strategic Recommendations? Other? Please inform us by taking our survey. 14
  • 15. Frost & Sullivan on Twitter and Facebook Find us @Frost_Sullivan on Twitter Become a fan of Frost & Sullivan on Facebook 15
  • 16. For Additional Information Katja Feick Noel Anderson Corporate Communications European Vice President Healthcare New Business Development 0049 (0) 69 7703343 +44 (0)207 343 8389 katja.feick@frost.com noel.anderson@frost.com Siddharth Saha Director of Research Healthcare + 44 (0) 207 343 8374 siddharth.saha@frost.com 16